Sign up
Pharma Capital

'The best is yet to come' for Phivida Holdings, says President Belfontaine

John Belfontaine, president and executive chairman of Phivida Holdings (CSE:VIDA), talks Proactive's Andrew Scott through the formation of the company and the management team which he describes as 'second-to-none'.

First trading as a public company in December 2017 they've moved quickly, securing deals with WeedMD Inc. (TSX-V:WMD) and Namaste Technologies Inc. ("Namaste") (CSE:N).

They've also just appointed Douglas Campbell as chief commercial officer. He brings with him extensive executive leadership, multi-channel marketing expertise and strong relationships with some of the largest food and beverage distributors and retailers in the world.

''Phivida has the brand, the product quality and standards necessary to cross over into the main stream'', Belfontaine says.

''We're excited about being in the pursuit of being that first crossover brand''.

 

View full VIDA profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.